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Sex Female Female Female Male Female
Age, y 45 41 60 55 58
Liver disease AIH AIH AIH AIH PBC
Liver stiffness, kPa 5.8 4.4 5.2 40.0 4.3
CAP, dB/m 161 165 274 185 159
Cirrhosis No No No Yes No
Arterial hypertension No No No No No
Diabetes mellitus No Yes No No No
Obesity No No Yes No No
Rheumatologic disease No No No No Yes
Prednisone, mg/d 8.75 6.25 2.5 50 5a




No No Yes Yes No
Hospitalization No No No No No
Workingc Yes Yes No Yes No
SARS-CoV-2
management
Hospitalization Yes No No Yes No
Hydroxychloroquine Yes Yes Yes Yes Yes
Lopinavir/ritonavir Yes No No Yes No
Azithromycin No Yes Yes No No
Outcome Alive Alive Alive Alive Alive
NOTE. Each patient was assigned a number.
AIH, autoimmune hepatitis; CAP, controlled attenuation parameter; PBC, pri-
mary biliary cholangitis; SARS-CoV-2, severe acute respiratory syndrome
coronavirus 2.
aImmunosuppressive therapy for undifferentiated connective tissue disease.
bIn late February 2020.
cPatients 1 and 2 had been working as a cashier (patient 1 at a restaurant and
patient 2 at a grocery store). Patient 4 had been working from home.
Abbreviations used in this paper: AIH, autoimmune hepatitis; COVID-19,
coronavirus disease 2019; PBC, primary biliary cholangitis; SARS-CoV-2,
severe acute respiratory syndrome coronavirus 2.
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https://doi.org/10.1016/j.cgh.2020.05.047Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) is a virus responsible for a variety of
clinical manifestations that, besides the lungs, can
involve several other organs, leading to both mild and
severe complications.1–3
There is scarce information regarding the interaction
between pre-existing liver disease and SARS-CoV-2
infection; specifically, there is no demonstration that
patients with autoimmune hepatitis (AIH) and primary
biliary cholangitis (PBC) are at higher risk of coronavirus
disease 2019 (COVID-19). One major difficulty in
addressing these issues has been the limited access to
outpatient clinics because of the pandemic, with deferral
of all routine follow-up visits.
Here, we report our experience on telemedicine
conducted by hepatologists in a tertiary-care Center for
Liver Disease of a University Hospital in Northern Italy
for a 2-week period during the COVID-19 pandemic.
Methods
From April 1 to 17, 2020, all patients with a previous
diagnosis of AIH or PBC who were under follow-up care
at our tertiary-care Center for Liver Disease at the Uni-
versity Hospital in Novara (in eastern Piedmont, close to
Lombardy) were included consecutively in this study.
They underwent a telephone survey to state whether
they had experienced symptoms related to SARS-CoV-2
infection, had been cured at home, or had been hospi-
talized for COVID-19 during the epidemic
(Supplementary Methods).
Results
Of 141 patients (73with AIH, 68with PBC), all except 3
patients (2 with AIH, 1 with PBC) answered the telephone
survey described earlier. Demographic and clinical fea-
tures of included patients are shown in Supplementary
Table 1.
Figure 1. Dynamic changes in liver function tests in the 2 hospitalized patients with COVID-19: last available laboratory tests
before admission, during hospitalization at day 5 of treatment with lopinavir/ritonavir and hydroxychloroquine, and at hospital
discharge after 48 to 72 hours from the end of therapy. Aspartate aminotransferase (AST): normal range, 0 to 40 U/L; alanine
aminotransferase (ALT): normal range 0 to 40 U/L; g-glutamyl transpeptidase (GGT): normal range, 0 to 50 U/L; albumin:
normal range, 34 to 48 g/L; total bilirubin: 0.3 to 1.2 mg/dL.
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with an immunosuppressive regimen (prednisone with/
without azathioprine).
All PBC patients were on ursodeoxycholic acid treat-
ment, 5 patients received obeticholic acid in addition to
ursodeoxycholic acid. Five patients (4 with AIH, 1 with
PBC) developed symptomatic SARS-CoV-2 infection,
diagnosed by a nasal swab. Demographic and clinical
features of these patients are shown in Table 1.
Two AIH patients (1 cirrhotic man who had an acute
onset of AIH and was under high-dose steroids, as per
induction protocol, and a woman in biochemical
remission being treated with prednisone) developed
respiratory failure as a result of COVID-19 pneumonia
with the need for hospitalization. They received com-
bination treatment with lopinavir/ritonavir and
hydroxychloroquine and fully recovered (Table 1).
During hospitalization, their liver enzyme levels were
monitored (Figure 1).
Three additional patients (2 with AIH, 1 with PBC)
developed a fever and cough without respiratory failureand were treated at home under mandatory quarantine,
and treated with hydroxychloroquine (Table 1) with full
recovery. All 3 patients experienced intense fatigue,
anosmia, and 1 patient also had diarrhea.Conclusions
To our knowledge, the real impact of COVID-19 in
patients with autoimmune liver diseases has not been
fully investigated.4 This pandemic has outlined the need
to face a deep change in hospital organization to pre-
vent a further spread of infection. The European Asso-
ciation for the Study of the Liver-European Society of
Clinical Microbiology and Infectious Diseases position
paper endorsed telemedicine in the outpatient setting
to avoid nosocomial dissemination of SARS-CoV-2.5 Our
study attempted to investigate the outbreak of SARS-
CoV-2 infection in a cohort of patients affected by
autoimmune liver diseases in a high COVID-
19–prevalence area.
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(3.6%) had evidence of SARS-CoV-2 infection.
The overall incidence in our cohort resulted in
approximately 7 and 5 times higher than estimated
rates in Piedmont and Lombardy (by April 21 was
approximately 0.50% and 0.67%, respectively).6,7
However, these findings need to be interpreted with
caution because it is likely that true infection rates in
the general population have been grossly under-
estimated. Moreover, half of the patients presented
were older than age 63 years, and only 25% were
younger than age 50 years. The patients also were
unbalanced with regard to sex, with a large predomi-
nance of women. Thus, the extent to which they can be
compared with the general reference population is
limited. Rates of COVID-19 were 5.6% among patients
with AIH (11 and 8 times higher compared with official
estimates in Piedmont and Lombardy, respectively) and
1.5% among PBC patients. The patients with AIH suf-
fered COVID-19 more frequently than patients with
PBC, maybe because of immunosuppressive treatment.
Our data on incidence seemed a little bit higher than
the preliminary data reported by D’Antiga.8
The outcomes of our patients affected by COVID-19
were favorable. In fact, this study attempted to assess
the outbreak and outcome of SARS-CoV-2 infection in all
consecutive patients with AIH or PBC followed up in a
single center.
In conclusion, our study emphasized the usefulness of
telemedicine for maintaining the continuity of care
among patients with autoimmune liver diseases during
the pandemic. Finally, our study showed quite low
rates of symptomatic SARS-CoV-2 infection, with
overall favorable outcomes among patients with AIH
and PBC.Supplementary Material
Note: To access the supplementary material accom-
panying this article, visit the online version of Clinical
Gastroenterology and Hepatology at www.cghjournal.org,
and at https://doi.org/10.1016/j.cgh.2020.05.047.References
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All patients were asked questions about the
following: previous vaccination for influenza virus; job;
recent traveling; contact with patients with COVID-19
(family/close friends/colleagues); onset of the
following symptoms compatible with SARS-2-CoV infec-
tion: fever, cough, chest pain, fatigue, arthralgia, myal-
gias, nausea, diarrhea, anosmia, ageusia, headache,
syncope, sinusitis, or rhinitis; de novo onset of symptoms
of liver disease: pruritus, jaundice, abdominal pain, in-
crease of abdominal circumference, or edema; immuno-
suppressive drug dosage (steroid and azathioprine) and
information about recent modifications or a stable doseSupplementary Table 1. Demographic and Clinical Features






Female, n 60 (84%) 66 (98%)
Age, ya 64 (21–87) 63 (37–89)
Liver stiffness, kPaa 6.2 (2.4–40.0) 5.9 (2.3–39.5)
Liver stiffness, >10 kPa, n 11 (15%) 6 (9%)
CAP, dB/ma 223 (137–366) 204 (89–312)
CAP, >280 dB/m, n 7 (10%) 3 (4%)
Cirrhosis, n 13 (18%) 6 (9%)
Decompensated liver disease, n 0 (0%) 0 (0%)
Arterial hypertension, n 27 (38%) 24 (36%)
Diabetes mellitus, n 14 (20%) 7 (10%)
Obesity, n 16 (22%) 14 (21%)
Rheumatologic disease, n 1 (1%)b 10 (15%)c
Prednisone, mg/da 6.25 (1.25–50) –
Azathioprine, mg/da 50 (25–125) –
Vaccination for influenza, n 7 (10%) 5 (7%)
Job during COVID-19 pandemic
Working from home or
unemployed, n
62 (87%) 64 (95%)
Medical doctor or nurse, n 4 1
Salesperson or cashier, n 3 2
AIH, autoimmune hepatitis; CAP, controlled attenuation parameter; COVID-19,
coronavirus disease 2019; PBC, primary biliary cholangitis.
aMedian (range).
bUndifferentiated connective tissue disease.
cEight patients had systemic sclerosis, 1 patient had undifferentiated con-
nective tissue disease, and 1 patient had systemic lupus erythematosus.for AIH patients; ursodeoxycholic acid and obeticholic
acid dosage and information about recent modifications
or a stable dose for PBC patients; and latest laboratory
investigations including liver biochemistry. During the
telephone call, the hepatologists advised their patients
not to reduce or stop ongoing treatment with immuno-
suppressive drugs. When necessary, a drug prescription
was delivered by a certified hospital e-mail box.
Of 141 patients (73 with AIH, 68 with PBC), all but 3
patients (2 with AIH, 1 with PBC) answered the tele-
phone survey. Regarding the 3 patients who we were not
able to reach by telephone, we connected with their
families and we were reassured about their health status.
However, we did not include them in this study.
